Clinical trialNCT01713738CompletedPhase 1/PHASE2Interventional

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

SponsorNeufeld, Ellis J, MD, PhDEnrollment36Idiopathic Thrombocytopenic Purpura (ITP)Immune Thrombocytopenic Purpura (ITP)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages 18 months to 18 years, who have severe, chronic ITP. Eligible patients with either primary or secondary ITP are treated with rituximab once a week for 4 doses, and then followed for up to one year. Response is defined as having a platelet count greater than or equal to 50,000/mL on four consecutive weekly measures beginning anytime in weeks 9 - 12.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ellis J Neufeld, MD, PhD
Boston Children's Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla, Mattel Children'S Hospital
Los Angeles, California, United States
Stanford University School of Medicine
Palo Alto, California, United States
University of California, San Francisco
San Francisco, California, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Children'S Hospital Boston
Boston, Massachusetts, United States
Van Eslander Cancer Center, St. John Hospital
Detroit, Michigan, United States
Weill Medical College at Cornell University
New York, New York, United States
Southwestern Medical Center at Dallas
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rituximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2003
Primary completion: 31 Dec 2005
Completion: 31 Dec 2005
Last update posted: 9 Nov 2012
Registered enrollment: 36
Registry id: NCT01713738

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.